CSL Seqirus, a subsidiary of the leading Australian biotechnology company CSL, has announced the approval of neffy® adrenaline (epinephrine) nasal spray in Australia. This innovative treatment is now available for the emergency management of anaphylaxis in adults and children weighing 15 kg and over, aged four years and older. Anaphylaxis is a severe allergic reaction that can occur after exposure to allergens such as certain foods, medications, and insect stings, posing a significant risk if not treated promptly with adrenaline.
Designed for rapid action, adrenaline works by alleviating symptoms associated with anaphylaxis, including throat swelling, airway obstruction, and maintaining cardiovascular stability. The incidence of anaphylaxis has been on the rise, with Australia recording one of the highest rates of hospital admissions for this condition in the developed world. Between 2015 and 2020, there was a reported 51% increase in emergency department visits and a 35% rise in hospitalizations due to anaphylaxis.
Significance of neffy® Approval
The introduction of neffy marks a significant advancement in the available treatment options for anaphylaxis, as it provides a needle-free alternative to traditional adrenaline injections. Professor Connie Katelaris, a prominent allergist in New South Wales, emphasized the importance of this approval, stating that it offers patients and healthcare providers a new method for managing this challenging condition. This development is particularly noteworthy as it is the first new method of administering adrenaline approved in Australia in over 30 years.
Expert Perspectives on Anaphylaxis Management
Maria Said, the Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia, highlighted the critical need for effective management of anaphylaxis in everyday situations. She noted that individuals with allergies must often navigate daily life with caution, from dining out to participating in social events. The availability of neffy enables patients and their healthcare professionals to choose an adrenaline delivery method that best suits their individual needs.
Dr. Jonathan Anderson, Executive Medical Director at CSL Seqirus, expressed optimism regarding the accessibility of neffy, stating that the company is committed to working with healthcare stakeholders to ensure that this treatment is widely available. He acknowledged the collaborative efforts of various allergy stakeholders in preparing for the rollout of neffy and the importance of evaluating its potential for funding to expand access across Australia.
What’s Next for neffy®?
As part of its rollout, CSL Seqirus has submitted an application for neffy to be subsidized and listed on the Pharmaceutical Benefits Scheme (PBS), with a decision expected in March 2026. It is crucial for patients to utilize neffy at the first signs of anaphylaxis and to seek immediate emergency medical assistance following its use for further monitoring and treatment.
Common side effects associated with neffy include headache, nasal discomfort, throat irritation, and feelings of jitteriness. As with all medications, patients should consult their healthcare provider regarding the most appropriate treatment options for managing their conditions.
Understanding Anaphylaxis
Anaphylaxis is characterized by a severe, rapid-onset allergic reaction that can affect multiple body systems, including the skin, respiratory, gastrointestinal, and cardiovascular systems. Symptoms may include difficulty breathing, swelling of the tongue or throat, persistent cough, and signs of shock such as dizziness or loss of consciousness.
Awareness and preparedness are key in managing anaphylaxis effectively. Healthcare organizations are updating their resources and training regarding anaphylaxis to include the new treatment options represented by neffy.
As Australia embarks on this new chapter in anaphylaxis management, patients, families, and healthcare providers alike are encouraged to stay informed about the latest developments in treatment and care.
For more information about neffy and its application, please visit CSL Seqirus.
Disclaimer: The information provided in this article is for informational purposes only and should not be considered as professional medical advice. Always consult a healthcare provider for medical advice and treatment.
